Wednesday, July 8, 2026

pharma · Dermatomyositis · Diffuse Cutaneous Systemic Sclerosis · CRBP

Corbus Pharmaceuticals

Corbus Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

500 River Ridge Dr, Norwood, Massachusetts 02062, US HQ
2014 Founded
57 Employees
Public company Type
CRBP · NYSE Ticker
Company details
Status
Public
HQ
500 River Ridge Dr, Norwood, Massachusetts 02062, US
Founded
2014
Employees
57
Programs
11
Drugs
3
Patents
6
Intelligence · Clinical Programs

Corbus Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Corbus Pharmaceuticals.

Corbus Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Lenabasum 20 mg

    Corbus Pharmaceuticals Holdings

    Dermatomyositis

    phase 3 small molecule completed

    1 trial
  2. Lenabasum 5 mg

    Corbus Pharmaceuticals Holdings

    Diffuse Cutaneous Systemic Sclerosis

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Corbus Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.